È stata testata con successo sui primi pazienti una terapia che sfrutta un virus modificato per contrastare il glioblastoma, un grave tumore del cervello.
AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, 20 to 24 October 2023.
Cell therapy in oncology has been spearheaded by the development of therapeutic chimeric antigen receptor (CAR)‑T cells, created by isolating and modifying a patient’s T cells to target their cancer.
In questo progetto l'assegnista dovrà applicare metodi di analisi di dati metabolomici per lo studio del cancro e/o per lo sviluppo di farmaci. Tali dati saranno ottenuti principalmente tramite spettroscopia di risonanza magnetica nucleare.
First Phase III results for AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody drug conjugate demonstrated statistically significant improvement in progression-free survival vs. standard chemotherapy in previously treated locally advanced or metastatic disease
